Hetrombopag Olamine + Hetrombopag Olamine ;Hetrombopag Olamine Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Patients With Chemotherapy-Induced Thrombocytopenia
Conditions
Patients With Chemotherapy-Induced Thrombocytopenia
Trial Timeline
Feb 1, 2026 → Jun 1, 2029
NCT ID
NCT07286032About Hetrombopag Olamine + Hetrombopag Olamine ;Hetrombopag Olamine Placebo
Hetrombopag Olamine + Hetrombopag Olamine ;Hetrombopag Olamine Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Patients With Chemotherapy-Induced Thrombocytopenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07286032. Target conditions include Patients With Chemotherapy-Induced Thrombocytopenia.
What happened to similar drugs?
18 of 20 similar drugs in Patients With Chemotherapy-Induced Thrombocytopenia were approved
Approved (18) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07286032 | Phase 3 | Recruiting |
Competing Products
20 competing products in Patients With Chemotherapy-Induced Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 32 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| ASP8825 | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP7991 | Astellas Pharma | Phase 1 | 29 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 40 |
| ATG-F | Astellas Pharma | Approved | 43 |
| Celecoxib | Astellas Pharma | Pre-clinical | 26 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| FK949E | Astellas Pharma | Phase 1 | 29 |